Ikarian Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Ikarian Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$625K	Buy	+28,099	New	+$672K	0.05%	122
2023 Q2	–	Sell	-60,000	Closed	-$1.13M	–	123
2023 Q1	$1.13M	Sell	60,000 -265,000	-82%	-$5.05M	0.26%	72
2022 Q4	$5.17M	Hold	325,000	–	–	1.25%	28
2022 Q3	$5.32M	Buy	+325,000	New	+$5.26M	1.06%	34
2022 Q2	–	Sell	-1,882	Closed	-$46K	–	138
2022 Q1	$46K	Buy	1,882 +117	+7%	+$2.83K	0.01%	185
2021 Q4	$42K	Sell	1,765 -280,000	-99%	-$5.63M	0.01%	175
2021 Q3	$4.68M	Buy	281,765 +71,899	+34%	+$1.39M	0.33%	70
2021 Q2	$5.12M	Buy	209,866 +203,858	+3,393%	+$4.6M	0.41%	68
2021 Q1	$155K	Sell	6,008 -50,000	-89%	-$2.2M	0.01%	275
2020 Q4	$3M	Hold	56,008	–	–	0.13%	132
2020 Q3	$2.31M	Buy	56,008 +10,000	+22%	+$432K	0.17%	108
2020 Q2	$2.23M	Buy	+46,008	New	+$2.21M	0.18%	103

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Ikarian Capital's ACAD Position: Q1 2026 in Review

Ikarian Capital opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2026: 28,099 shares worth $625K. The stake represents 0.05% of the portfolio and ranks #122 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in ACAD as recently as Q1 2023.

Ikarian Capital first reported a position in ACAD in Q2 2020 and has held it in 12 quarters since. The position peaked at $5.32M in Q3 2022. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Ikarian Capital held 28,099 shares of Acadia Pharmaceuticals worth $625K as of Q1 2026.
Acadia Pharmaceuticals was a new Ikarian Capital position in Q1 2026.
Acadia Pharmaceuticals made up 0.05% of Ikarian Capital's portfolio in Q1 2026, its #122 holding.
Ikarian Capital first reported a position in Acadia Pharmaceuticals in Q2 2020 and has held it in 12 quarters since.
Ikarian Capital's Acadia Pharmaceuticals position peaked at $5.32M in Q3 2022.
340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.